HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF
“A fund that captures companies at the cross-roads of
medicine and technology and who are shaping the future of healthcare" Anthony Ginsberg, CEO, GinsGlobal
HAN-GINS Indxx Healthcare
Megatrend Equal Weight UCITS ETF (WELL) is a UCITS compliance ETF domiciled in
WELL tracks the Indxx Global NextGen Healthcare Index, an index designed to capture securities at the cross-roads
of medicine and technology which are shaping the future of healthcare.
In a single trade, WELL delivers
exposure to over 100 global companies from the following 10 sub-themes:
robotics; nanotechnology; genome sequencing; healthcare trackers; biological
engineering; bioinformatics; neuroscience; medical devices; telemedicine and
Please remember that the value of
your investment may go down as well as up and past performance is no indication
of future performance.
View Related Articles
Healthcare innovations are well positioned to deliver strong growth rates as the traditional healthcare sector is undergoing significant change and modernisation in the wake of Covid and thanks to the availability of new technologies. WELL has been updated in 2021 to include innovative themes such as Telemedicine and Healthcare Analytics, which have both proved immensely important in tackling Covid-19.
WELL avoids concentration in larger stocks by using an equal weighting methodology. This enables smaller yet innovative companies to better to contribute to WELL’s performance. The number of companies in each sector will be capped, subject to avoid an overreliance on any-one subtheme.
WELL only includes companies that comply with the UN Global Compact principles, who are not involved with controversial weapons and who have low fossil fuel exposure.
+44(0) 203 794 1800
HANetf Ltd, City Tower, 40 Basinghall St,
London, EC2V 5DE
The price of any Shares or the value of an investment in ETPs may go up or down and an investor may not get back the amount invested. Past performance is not a reliable indicator of future performance. This material is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any financial instrument or product or to adopt any investment strategy. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice.
These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.
Select Your Country
Please choose one of the following options: